News coverage about AVEO Pharmaceuticals (NASDAQ:AVEO) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. AVEO Pharmaceuticals earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.6999222527481 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have effected Accern Sentiment’s scoring:
Shares of NASDAQ:AVEO opened at $2.64 on Monday. AVEO Pharmaceuticals has a 52-week low of $0.57 and a 52-week high of $4.24. The firm has a market capitalization of $307.87, a P/E ratio of -16.50 and a beta of 1.32. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of -0.45.
AVEO has been the subject of a number of recent analyst reports. BidaskClub lowered shares of AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, January 9th. Zacks Investment Research upgraded shares of AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. Finally, B. Riley restated a “buy” rating and set a $5.00 price target on shares of AVEO Pharmaceuticals in a research report on Tuesday, January 16th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $4.05.
In related news, major shareholder Ravi Viswanathan bought 685,676 shares of the business’s stock in a transaction that occurred on Friday, April 6th. The stock was bought at an average cost of $2.24 per share, for a total transaction of $1,535,914.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Peter J. Barris bought 920,976 shares of the business’s stock in a transaction that occurred on Tuesday, April 10th. The stock was bought at an average price of $2.30 per share, with a total value of $2,118,244.80. The disclosure for this purchase can be found here. 4.70% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: “AVEO Pharmaceuticals (AVEO) Given Daily News Impact Rating of 0.08” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/23/aveo-pharmaceuticals-aveo-given-daily-news-impact-rating-of-0-08.html.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.